Arnold Wendy S
Known title: Chief People OfficerCIK: 0001802649
Associated companies
Transaction History
| KRRO | ▼ Sell | Open Market | 5,638 | $9K | 7/6/2022 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 15,000 | — | 7/5/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,326 | $5K | 2/22/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,209 | $5K | 2/18/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,118 | $5K | 2/17/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,057 | $5K | 2/16/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,168 | $5K | 2/15/2022 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 15,000 | — | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.